Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European Ambulance Acute Coronary Syndrome Angiox Trial (EUROMAX)
2008-007290-20Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Nov 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bivalirudin in acute coronary syndrome (ACS) and myocardial infarction (MI) (2 arms), sponsored by The Medicines Company. Primary endpoint: Composite of death and non-CABG-related protocol major bleeding at 30 days. Started Nov 2009; status: completed.
02
Drugs
bivalirudin
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on 2008-007290-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007290-20.